Abstract
A subgroup of patients with metastatic carcinomas of unknown origin may benefit from combination chemotherapy. The relevance of immunohistochemistry in detecting such patients was investigated. Immunohistochemical studies with a panel of antibodies were performed on the tissue specimens of 41 patients having a light-microscopic diagnosis of poorly differentiated adenocarcinoma or undifferentiated carcinoma of unknown origin, who had been treated with cisplatin-containing chemotherapy. The study aimed to answer the following questions: (a) Can the tissue type of the tumor be verified? (b) Can a primary organ site be identified? (c) Can a prognostic immunohistochemical profile be recognized? The original diagnosis had to be changed in 2 of the 41 patients, who turned out to have a malignant lymphoma and neuroblastoma, respectively. The primary site was diagnosed in a patient with prostate cancer, whereas in one case the diagnosis could be narrowed down to a neuroendocrine tumor. No certain immunohistochemical profile with prognostic significance could be identified. It was concluded that immunohistochemistry should be routinely used in cases of undifferentiated carcinoma of unknown primary origin to verify the histological diagnosis and to select the appropriate therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ßHCG :
-
β-human chorionic gonadotropin
- AFP :
-
α-fetoprotein
- CEA :
-
careinoembryonic antigen
- PSA :
-
prostate-specific antigen
- PZF :
-
prostatic acid phosphatase
References
Didolkar MS, Fanous N, Elias EG, Moore RH (1977) Metastatic carcinomas from occult primary tumor: a study of 254 patients. Ann Surg 186:625–630
Domagala W, Lasota J, Bartowiak J, Weber K, Osborn M (1990) Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 136:219–227
Gaast A van der, Verweij J, Henzen-Logmans SC, Stoter G (1990) Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol 1:119–122
Goslin R, O'Brien MJ, Steele G, Mayer R, Wilson R, Corson JM, Zamcheck N (1981) Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal carcinoma. Am J Med 71:246–253
Greco FA, Hainsworth JD (1990) Carcinoma of unknown primary site. Ann Oncol 1:98–99
Greco FA, Vaughn WK, Hainsworth JD (1986) Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 104:547–553
Hainsworth JD, Dial TW, Greco FA (1988) Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site. Am J Clin Oncol 11: 138–145
Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA (1991) Poorly differentiated carcinoma of unknown primary site: Clinical usefulness of immunoperoxidase staining. J Clin Oncol 9:1931–1938
Hainsworth JD, Johnson DH, Greco FA (1992a) Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 10:912–922
Hainsworth JD, Johnson DH, Greco FA (1992b) The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site. Semin Oncol 19 [Suppl 5]:54–58
Henzen-Logmans SC, Mullink H, Vennegoor C, Hilgers J, Oort J, Meijer JLM (1987) Classification of routinely processed anaplastic large cell tumours with a small panel of antibodies. An immunohistochemical study with clinical follow-up. Histol Histopathol 2:107–118
Holmes FF, Fouts TL (1990) Metastatic cancer of unknown primary site. Cancer 26:816–820
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457–481
Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielman N, Rouesse J (1988) Early metastatic cancer of unknown primary origin at presentation: a clinical study of 302 consecutive autopsied patients. Arch Intern Med 148: 2035–2039
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170
Neumann KH, Nystrom JS (1982) Metastatic cancer of unknown origin; nonsquamous cell type. Semin Oncol 4:427–434
Nystrom JS, Weiner JM, Wolf RM, Bateman JR, Viola MV (1979) Identifying the primary site in metastatic cancer of unknown origin: inadequacy of roentgenographic procedures. JAMA 241:381–383
Raymond WA, Leong A S-Y (1989) Vimentin — a new prognostic parameter in breast carcinoma? J Pathol 158:107–114
Ultmann JE (1991) Cancer of unknown primary site. J Cancer Res Clin Oncol 117:505–509
Vennegoor C, Calafat J, Hageman Ph, van Buitenen F, Janssen H, Kolk A, Rumke Ph (1985) Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI/C-3. Int J Cancer 35:287–295
WHO (1979) Handbook of reporting results of cancer treatment: WHO offset Publ 48
Woods RL, Fox RM, Tattersall MHN, Levi JA, Brodie GN (1980) Metastatic adenocarcinomas of unknown primary: a randomized study of two combination-chemotherapy regimens. N. Engl J Med 303:87–89
Zarbo RJ, Gown AM, Nagle RB, Visscher DW, Crissman JD (1990) Anomalous cytokeratin expression in malignant melanoma: one- and two-dimensional Western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol 3:494–501
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van der Gaast, A., Verweij, J., Planting, A.S.T. et al. The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary. J Cancer Res Clin Oncol 122, 181–185 (1996). https://doi.org/10.1007/BF01366960
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01366960